- Conditions
- Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
- Interventions
- Donor Hematopoietic Stem and Progenitor Cell Infusion
- Biological
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,174
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
- Interventions
- Cyclophosphamide, Fludarabine, Melphalan, Mesna, Rituximab, Stem Cell Transplantation, Thiotepa, Tacrolimus, Mycofenolate mofetil, G-CSF
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Kidney Disease, Kidney Disease, Kidney Disease, Chronic, Chronic Kidney Disease (CKD), CKD
- Interventions
- Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione IV, Glutathione Spray, Placebo IV, Placebo Glutathione IV, Placebo Spray
- Biological · Drug · Other
- Lead sponsor
- Adia Med of Winter Park LLC
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Winter Park, Florida
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
- Interventions
- BPX-501 dose 1, Rimiducid, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4, SCT
- Biological · Drug · Procedure
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2032
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Buffalo, New York • New York, New York + 4 more
- Conditions
- Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Systematic chemotherapy and antibodies, Allogeneic stem cell transplantation, Miltenyi CliniMACS
- Drug · Procedure · Device
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
- Interventions
- pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection, Involved-site radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 10
- States / cities
- Duarte, California • Stanford, California • Miami, Florida + 7 more
- Conditions
- Fanconi Anemia, Severe Aplastic Anemia
- Interventions
- CAMPATH-1H, Anti-CD45, Fludarabine, Stem cell infusion
- Biological · Drug · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Mesenchymal Stem Cells (MSCs), Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)
- Biological · Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Lymphoma
- Interventions
- carmustine, cyclophosphamide, etoposide, pharmacological study, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Drug · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Leukemia, Solid Tumors
- Interventions
- Clinimacs Cell Separation System, conditioning chemotherapy, DLI
- Device · Drug · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Neuroblastoma
- Interventions
- Carboplatin, Etoposide, Melphalan, Stem Cell Infusion, ClinicMACS
- Drug · Procedure · Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sinusoidal Obstruction Syndrome, Veno-occlusive Disease, Bone Marrow Transplant Complications
- Interventions
- Defibrotide
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, Diffuse Large B-Cell Lymphoma, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Interventions
- Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Clearing Agent, Cytarabine, Etoposide, Indium In 111-DOTA-Biotin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Yttrium Y 90-DOTA-Biotin
- Biological · Procedure · Drug + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
- Interventions
- First Allogeneic Bone Marrow Transplant (BMT), Leuprolide, 18F FLT, Cyclophosphamide, Methotrexate, Tacrolimus, Total Body Irradiation, Busulfan, Fludarabine, Second Allogeneic Bone Marrow Transplantation
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland • Oklahoma City, Oklahoma
- Conditions
- Renal Transplantation, Mesenchymal Stem Cells
- Interventions
- Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion
- Biological · Other
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- Combination Product
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 9 more
- Conditions
- Hematologic Malignancies
- Interventions
- Drugs Cyclophosphamide, Fludarabine, Thiotepa, Tacrolimus, Mycophenolate mofetil
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Granulomatous Disease
- Interventions
- Sirolimus, Donor peripheral blood stem cells., Cyclophosphamide post transplant, Total body 200cGy, Cyclophosphamide, Fludarabine, Busulfan
- Drug · Biological · Radiation
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Interventions
- EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion)
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Westwood, Kansas • Columbus, Ohio
- Conditions
- MDS, Immunodeficiency, GATA2
- Interventions
- Cyclophosphamide (CTX, Cytoxan), Fludarabine(Fludara,Berlex Laboratories), Total Body Irradiation (TBI), Allogeneic Hematopoietic Stem Cell (HSC), Equine Anti-Thymocyte Globulin
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan
- Drug · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 2 Months and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2038
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pediatric Hematologic Malignancies
- Interventions
- Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- Cytarabine, Intrathecal Triples, HPC-A
- Drug · Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Myeloid Diseases
- Interventions
- Antithymocyte globulin (Rabbit), fludarabine, total body irradiation, cyclophosphamide, Rituxan, Allogeneic Hematopoietic Stem Cell Transplantation
- Drug · Radiation · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 2
- States / cities
- Middletown, New Jersey • New York, New York